Next Generation Targets in Inflammation and Immunity

This document is a technical report that discusses the evolution of treatment targets in the field of inflammation and immunity (I&I), particularly focusing on the shift from Tumor Necrosis Factor (TNF) inhibitors to Interleukin-17 (IL-17) and Interleukin-23 (IL-23) inhibitors. It outlines the historical context of TNF inhibitors, which have been foundational in treating various conditions such as rheumatoid arthritis and psoriasis since their introduction in 1998. The report details the challenges faced by TNF therapies, including non-response in patients and safety concerns, leading to a strategic pivot towards IL-17 and IL-23, which offer greater specificity and improved safety profiles. Additionally, it presents insights into other immune targets like JAK inhibitors and B-cell depletion strategies, while noting a recent spike in TNF-related clinical programs, which appears to be an anomaly rather than a resurgence of interest. The report concludes by explaining how the platform supports decision-makers in navigating these evolving treatment landscapes.